| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA890446 | A | Cytotoxicity against HUVEC after 24 hrs by MTT assay | Homo sapiens | 17 | cell-based format | Scientific Literature | ||
| 2. | ALA1794345 | F | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | Plasmodium falciparum | 170,142 | organism-based format | PubChem BioAssays | ||
| 3. | ALA2114861 | F | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen. (Class of assay: confirmatory) | 26,907 | assay format | PubChem BioAssays | |||
| 4. | ALA2114865 | F | PubChem BioAssay. Identification of Inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) | Homo sapiens | 408 | biochemical format | PubChem BioAssays | ||
| 5. | ALA2114881 | F | PubChem BioAssay. Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Primary and Confirmatory Screens. (Class of assay: confirmatory) | Homo sapiens | 2,057 | assay format | PubChem BioAssays | ||
| 6. | ALA2114736 | F | PubChem BioAssay. Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Counter Screen Coupled Enzyme. (Class of assay: confirmatory) | 1,364 | assay format | PubChem BioAssays | |||
| 7. | ALA2114780 | F | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | Homo sapiens | 58,727 | cell-based format | PubChem BioAssays | ||
| 8. | ALA1794486 | F | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | 10,834 | assay format | PubChem BioAssays | |||
| 9. | ALA1794580 | F | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | Plasmodium falciparum | 130,890 | organism-based format | PubChem BioAssays | ||
| 10. | ALA1794584 | F | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | 63,980 | assay format | PubChem BioAssays | |||
| 11. | ALA2114788 | F | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | Homo sapiens | 103,470 | assay format | PubChem BioAssays | ||
| 12. | ALA2114931 | F | PubChem BioAssay. qHTS of GLP-1 Receptor Agonists. (Class of assay: confirmatory) | Homo sapiens | 3,540 | assay format | PubChem BioAssays | ||
| 13. | ALA1016905 | F | Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by [G-3H]hypoxanthine uptake | Plasmodium falciparum | 22 | organism-based format | Scientific Literature | ||
| 14. | ALA1054500 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 15. | ALA1054501 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 16. | ALA1054502 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 17. | ALA1054503 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 18. | ALA1054504 | F | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | Homo sapiens | 13,467 | cell-based format | GSK Malaria Screening | ||
| 19. | ALA1054505 | F | GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested | 13,467 | assay format | GSK Malaria Screening | |||
| 20. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | organism-based format | Novartis Malaria Screening |
The page will load shortly, Thanks for your patience!